Identification of Shared Diagnostic Biomarkers LCN2 and DUOX2 for Inflammatory Bowel Disease and Cholangiocarcinoma Through Integrative Bioinformatics and Machine Learning

通过整合生物信息学和机器学习方法鉴定炎症性肠病和胆管癌的共有诊断生物标志物LCN2和DUOX2

阅读:1

Abstract

BACKGROUND: Inflammatory bowel disease (IBD) is a common chronic inflammatory illness affecting the gastrointestinal tract. Cholangiocarcinoma (CCA) comprises a group of highly heterogeneous cancers originating from the biliary tract. Epidemiological evidence suggests a positive correlation between IBD and CCA. However, the pathological mechanisms are unestablished. This research aimed to identify common biomarkers and immune infiltration features in IBD and CCA to support early detection and development of targeted therapies. METHODS: Based on transcriptomic data from the GEO and TCGA databases, candidate genes were obtained by integrating differentially expressed genes (DEGs) with key modules derived from weighted gene co-expression network analysis (WGCNA). Hub genes were subsequently screened using four machine learning algorithms. A comprehensive validation of the hub genes (LCN2 and DUOX2) was performed through receiver operating characteristic (ROC) curve analysis, survival analysis, immune infiltration profiling (CIBERSORT), and drug sensitivity assessment. RESULTS: By overlapping DEGs with key WGCNA modules, thirteen candidate genes were obtained. Eight common hub genes (CCL11, CCL20, DUOX2, DUOXA2, LCN2, NOS2, PDZK1IP1, and TRIM40) were ultimately selected through integrated ML approaches. ROC analysis demonstrated that LCN2 and DUOX2 exhibited excellent diagnostic performance for both IBD and CCA, as reflected by high area under the curve values. CONCLUSION: This research confirmed that LCN2 and DUOX2 are key shared genes in the comorbidity of IBD and CCA. It also highlighted the distinct immune infiltration features between the two diseases. These findings provide novel perspectives on the pathogenesis of IBD and CCA, thereby offering a basis for early screening of CCA in individuals with IBD.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。